These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 32280433)

  • 1. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.
    Beck BR; Shin B; Choi Y; Park S; Kang K
    Comput Struct Biotechnol J; 2020; 18():784-790. PubMed ID: 32280433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
    Choi Y; Shin B; Kang K; Park S; Beck BR
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
    Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
    Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
    Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.
    Kang K; Kim HH; Choi Y
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32698440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
    Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W
    Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
    Copertino DC; Casado Lima BC; Duarte RRR; Powell TR; Ormsby CE; Wilkin T; Gulick RM; de Mulder Rougvie M; Nixon DF
    J Biomol Struct Dyn; 2022 Oct; 40(16):7367-7380. PubMed ID: 33734021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2.
    Alabdalaali MM; Hadi AM
    Arch Razi Inst; 2023 Jun; 78(3):935-941. PubMed ID: 38028857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
    Dallocchio RN; Dessì A; De Vito A; Delogu G; Serra PA; Madeddu G
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2435-2448. PubMed ID: 33755983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.
    Mahdi M; Mótyán JA; Szojka ZI; Golda M; Miczi M; Tőzsér J
    Virol J; 2020 Nov; 17(1):190. PubMed ID: 33243253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    More SA; Patil AS; Sakle NS; Mokale SN
    Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
    Magro P; Zanella I; Pescarolo M; Castelli F; Quiros-Roldan E
    Biomed J; 2021 Mar; 44(1):43-53. PubMed ID: 33608241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.